Biotech Startups

iFAST Diagnostics develops rapid antimicrobial susceptibility testing (AST) technology that delivers susceptibility test results in under 3 hours, significantly faster than the standard 40-hour process. The company serves clinical laboratories and hospitals to help combat antimicrobial resistance.

3 investors

Ikarovec is a biotech company focused on developing treatments for retinal diseases affecting vision. The company combines clinical expertise with preclinical research capabilities.

3 investors

3 investors

Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.

3 investors

ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company developing immune therapies for immune-excluded tumors, which resist standard PD-1 blockade. Its lead candidate, IMGS-001, is a cytotoxic immune checkpoint inhibitor aimed at cancers such as colorectal, ovarian, and non–small cell lung cancer.

3 investors

Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.

3 investors

Immuto Scientific uses patient-derived tissue models combined with computational structural proteomics and machine learning to identify disease-specific protein targets for drug discovery. The platform applies advanced mass spectrometry and molecular simulations to distinguish diseased from healthy tissues and accelerate therapeutic development.

3 investors

Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules. The company pursues partnerships, collaborations, and licensing opportunities to expand the therapeutic applications of its technology.

3 investors

Impetus Ag develops early- to late-stage agricultural technologies, with a focus on Bt discovery and development and insecticidal proteins for insect and pest control in crops. It operates in the agricultural biotech sector, building plant trait and biological R&D solutions.

3 investors

IMU Biosciences uses a multi-omic platform to measure over 100 million immune data points from a single blood sample, resolving 2,500 immune cell subsets to build a large-scale immune dataset. The company applies this "HD Immunology" approach to develop predictive tools for stem cell and organ transplantation and immuno-oncology, partnering with clinical research groups, pharma, biotech and diagnostics companies.

3 investors

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.

3 investors

Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2. The company focuses on drug development for patients with advanced and resistant cancers.

3 investors

Index Biosystems builds an AI platform for food safety and quality assurance (FSQA) teams in food manufacturing, combining AI agents that automate investigations and audit prep with BioTags — food-grade, DNA-labeled microbial tracers that generate molecular data for tracing material movement and validating sanitation. The platform maps facilities, SOPs, and testing programs into a knowledge graph so agents can reason about operations and shift food safety programs from reactive to predictive.

3 investors

INDIGO Biosciences is a life sciences company led by professionals with expertise in life sciences, business management, and operations.

3 investors

InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers. The company built proprietary platforms — Membrane Interactomics (MInt) for target discovery, ARRIS for proximity modalities using multi-specific antibody technology, and internal antibody discovery and engineering — to identify targets and design therapeutic molecules.

3 investors

iMicrobes uses synthetic biology to develop cost-effective sustainable materials and replace conventional manufacturing processes. The company focuses on circular economy principles, converting waste streams into value through biotechnology.

3 investors

InGel Therapeutics develops engineered cell therapies for complex retinal degenerative diseases, combining retinal precursor cells with a biomimetic hyaluronic acid and gelatin hydrogel delivery matrix that mimics the human vitreous. The company also runs Regenesis, a target discovery platform using single-cell proteomics to identify neuroprotective pathways in the eye.

3 investors

Ingenix builds an AI "Reasoning Engine" using an approach it calls Modality Fusion to integrate biological data across modalities and scales. It targets R&D decisions affecting clinical efficacy and safety outcomes in drug development, serving biotech and pharmaceutical research.

3 investors

Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer. The company operates in the biotherapeutics and drug development industry.

3 investors

Inoviv provides custom multiplexed LC-MS proteomics panels for biomarker discovery and analysis in drug discovery and development. The company delivers pre-validated mass spectrometry workflows with end-to-end support for research and clinical applications.

3 investors

3 investors

InsituGen develops cell-free bioassay technology for steroid hormone testing, offering a low-cost test to detect androgen and estrogen bioactivity in companion animal diagnostics. Its products include equine anti-doping and companion animal diagnostic tests, serving the animal health and diagnostics markets.

3 investors

inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.

3 investors

Inspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform. The company focuses on common cancers with high unmet need through small molecules and biologics.

3 investors